Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. jitc.bmj.com/content/14/1...
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial
Background Given the success of checkpoint inhibitor therapy in the advanced Merkel cell carcinoma (MCC) setting, there is interest in exploring immunotherapy as a neoadjuvant approach. We report the ...
jitc.bmj.com
January 16, 2026 at 10:19 AM
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. jitc.bmj.com/content/14/1...
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative #BreastCancer (TNBC) (PLANeT trial—Pembrolizumab Low dose in Addition to NACT in TNBC). www.annalsofoncology.org/article/S092...
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT tria...
Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard-of-care
treatment in non-metastatic triple-negative breast cancer (TNBC). Trials employing
reduced doses of immune checkpoint...
www.annalsofoncology.org
January 16, 2026 at 9:55 AM
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative #BreastCancer (TNBC) (PLANeT trial—Pembrolizumab Low dose in Addition to NACT in TNBC). www.annalsofoncology.org/article/S092...
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
https://www.vitaminrush.com/288330/linavonkibart-and-pembrolizumab-in-immune-checkpoint-blockade-resistant-advanced-solid-tumors-a-phase-1-trial/
Competing interests T.A.Y. reports …
https://www.vitaminrush.com/288330/linavonkibart-and-pembrolizumab-in-immune-checkpoint-blockade-resistant-advanced-solid-tumors-a-phase-1-trial/
Competing interests T.A.Y. reports …
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial - Vitamin Rush
Competing interests
www.vitaminrush.com
January 16, 2026 at 2:40 AM
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
https://www.vitaminrush.com/288330/linavonkibart-and-pembrolizumab-in-immune-checkpoint-blockade-resistant-advanced-solid-tumors-a-phase-1-trial/
Competing interests T.A.Y. reports …
https://www.vitaminrush.com/288330/linavonkibart-and-pembrolizumab-in-immune-checkpoint-blockade-resistant-advanced-solid-tumors-a-phase-1-trial/
Competing interests T.A.Y. reports …
🤖 Automated message
5 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-15.html
Changes: Lisocabtagene maraleucel, pembrolizumab, ropeginterferon alfa-2b, brexucabtagene autoleucel, bi...
5 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-15.html
Changes: Lisocabtagene maraleucel, pembrolizumab, ropeginterferon alfa-2b, brexucabtagene autoleucel, bi...
Updated Summary of Product Characteristics – Chemotherapy Updates
Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.
updates.chemo.org.uk
January 15, 2026 at 3:23 PM
🤖 Automated message
5 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-15.html
Changes: Lisocabtagene maraleucel, pembrolizumab, ropeginterferon alfa-2b, brexucabtagene autoleucel, bi...
5 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-15.html
Changes: Lisocabtagene maraleucel, pembrolizumab, ropeginterferon alfa-2b, brexucabtagene autoleucel, bi...
Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. www.redjournal.org/article/S036...
Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial
To evaluate the safety, feasibility, and clinical efficacy of stereotactic body radiation
therapy (SBRT) combined with pembrolizumab in patients with recurrent or metastatic
(R/M) head and neck squamo...
www.redjournal.org
January 15, 2026 at 2:26 PM
Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. www.redjournal.org/article/S036...
Canada is changing cervical cancer care — 3D‑printed radiation, less invasive hysterectomies, and immune therapies like pembrolizumab & Libtayo are giving patients new hope. Could these breakthroughs reshape cancer treatment worldwide? 🩺💉 #CervicalCancer #Oncology
January 15, 2026 at 5:01 AM
Canada is changing cervical cancer care — 3D‑printed radiation, less invasive hysterectomies, and immune therapies like pembrolizumab & Libtayo are giving patients new hope. Could these breakthroughs reshape cancer treatment worldwide? 🩺💉 #CervicalCancer #Oncology
Neoadjuvant Pembrolizumab Plus Chemotherapy in HR+/HER2– Breast Cancer
oncodaily.com/opinion/hr-h...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
oncodaily.com/opinion/hr-h...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
Neoadjuvant Pembrolizumab Plus Chemotherapy in HR+/HER2– Breast Cancer - OncoDaily
How immune modulation and treatment sequencing shape response to neoadjuvant immunotherapy in HR+/HER2– breast cancer.
oncodaily.com
January 14, 2026 at 8:58 PM
Neoadjuvant Pembrolizumab Plus Chemotherapy in HR+/HER2– Breast Cancer
oncodaily.com/opinion/hr-h...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
oncodaily.com/opinion/hr-h...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
->Nature | More from Lil Dr Glen EcoChat at BigEarthData.ai
->Nature | More from Lil Dr Glen EcoChat at BigEarthData.ai
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
The study protocol was approved by the institutional review boards (IRBs) and ethics committees at all participating sites: WCG IRB, LLC (Hartford, CT, USA), Mary Crowley Medical Research Center IRB (Dallas, TX, USA), The University of Texas MD Anderson Cancer...
www.nature.com
January 14, 2026 at 2:53 PM
🧬 Pembrolizumab in MSS–TMB-H mCRC: Real-world C-CAT data show poor outcomes vs MSI-H–TMB-H (OS 4.5 vs 33.6 mo; TTF 2.0 vs 10.6). Pembro underperformed FTD/TPI. High TMB alone ≠ benefit; responses limited to rare POLE-mutant MSS tumors. Avoid ICI outside this subset.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:51 PM
🧬 Pembrolizumab in MSS–TMB-H mCRC: Real-world C-CAT data show poor outcomes vs MSI-H–TMB-H (OS 4.5 vs 33.6 mo; TTF 2.0 vs 10.6). Pembro underperformed FTD/TPI. High TMB alone ≠ benefit; responses limited to rare POLE-mutant MSS tumors. Avoid ICI outside this subset.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
💊 LEAP-014 (AASLD 2025):
Adding lenvatinib to pembrolizumab + chemo did not improve survival in metastatic ESCC.
OS 17.6 vs 15.5 mo; PFS 7.2 vs 6.9 mo.
Similar toxicity, no biomarker benefit. Experts: no role for lenvatinib.
🧠 gastroagi.com/chat
Adding lenvatinib to pembrolizumab + chemo did not improve survival in metastatic ESCC.
OS 17.6 vs 15.5 mo; PFS 7.2 vs 6.9 mo.
Similar toxicity, no biomarker benefit. Experts: no role for lenvatinib.
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 7:11 AM
💊 LEAP-014 (AASLD 2025):
Adding lenvatinib to pembrolizumab + chemo did not improve survival in metastatic ESCC.
OS 17.6 vs 15.5 mo; PFS 7.2 vs 6.9 mo.
Similar toxicity, no biomarker benefit. Experts: no role for lenvatinib.
🧠 gastroagi.com/chat
Adding lenvatinib to pembrolizumab + chemo did not improve survival in metastatic ESCC.
OS 17.6 vs 15.5 mo; PFS 7.2 vs 6.9 mo.
Similar toxicity, no biomarker benefit. Experts: no role for lenvatinib.
🧠 gastroagi.com/chat
Study Activation! NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer.
January 12, 2026 at 7:01 PM
Study Activation! NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer.
🤖 Automated message
6 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-12.html
Changes: abemaciclib, trastuzumab, belumosudil mesilate, Lisocabtagene maraleucel, pembrolizumab
6 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-12.html
Changes: abemaciclib, trastuzumab, belumosudil mesilate, Lisocabtagene maraleucel, pembrolizumab
Updated Summary of Product Characteristics – Chemotherapy Updates
Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.
updates.chemo.org.uk
January 12, 2026 at 3:23 PM
🤖 Automated message
6 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-12.html
Changes: abemaciclib, trastuzumab, belumosudil mesilate, Lisocabtagene maraleucel, pembrolizumab
6 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-01-12.html
Changes: abemaciclib, trastuzumab, belumosudil mesilate, Lisocabtagene maraleucel, pembrolizumab
High-dose preoperative radiotherapy plus pembrolizumab increased T-cell infiltration in node-positive, higher-risk, HR-positive, HER2-negative early #breastcancer. Presented at the @sabcs.bsky.social #SABCS25, covered by @cancertherapyadv.bsky.social.
https://bit.ly/4qHawMh
#bcsm #SABCS2025
https://bit.ly/4qHawMh
#bcsm #SABCS2025
High-Dose Preoperative RT Plus ICI Stimulates T-Cell Infiltration in HR+, HER2- EBC - Oncology Nurse Advisor
This phase 2 trial explored whether preoperative RT combined with an immune checkpoint inhibitor may act as an immune stimulator, enhancing T-cell infiltration.
bit.ly
January 8, 2026 at 9:10 PM
High-dose preoperative radiotherapy plus pembrolizumab increased T-cell infiltration in node-positive, higher-risk, HR-positive, HER2-negative early #breastcancer. Presented at the @sabcs.bsky.social #SABCS25, covered by @cancertherapyadv.bsky.social.
https://bit.ly/4qHawMh
#bcsm #SABCS2025
https://bit.ly/4qHawMh
#bcsm #SABCS2025
Protein crystal growth experiments in microgravity helped optimize pembrolizumab for subcutaneous injection, cutting administration time from 2 hours to under 30 minutes. This advancement offers a more efficient treatment option for certain patients. 2/2
January 6, 2026 at 9:01 PM
Protein crystal growth experiments in microgravity helped optimize pembrolizumab for subcutaneous injection, cutting administration time from 2 hours to under 30 minutes. This advancement offers a more efficient treatment option for certain patients. 2/2
Sac-TMT Plus Pembrolizumab Nets BTD in China for First-Line PD-L1+ NSCLC
#lcsm #oncology
www.onclive.com/view/sac-tmt...
#lcsm #oncology
www.onclive.com/view/sac-tmt...
Sac-TMT Plus Pembrolizumab Nets BTD in China for First-Line PD-L1+ NSCLC | OncLive
Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.
www.onclive.com
January 6, 2026 at 5:53 PM
Sac-TMT Plus Pembrolizumab Nets BTD in China for First-Line PD-L1+ NSCLC
#lcsm #oncology
www.onclive.com/view/sac-tmt...
#lcsm #oncology
www.onclive.com/view/sac-tmt...
Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC @stolaney1.bsky.social @danafarber.bsky.social @harvardmed.bsky.social @winshipcancer.emory.edu #bcsm #oncology
www.onclive.com/view/sacituz...
www.onclive.com/view/sacituz...
Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC | OncLive
Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.
www.onclive.com
January 6, 2026 at 3:02 PM
Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC @stolaney1.bsky.social @danafarber.bsky.social @harvardmed.bsky.social @winshipcancer.emory.edu #bcsm #oncology
www.onclive.com/view/sacituz...
www.onclive.com/view/sacituz...
Kelun-Biotech's Sacituzumab Tirumotecan Receives Breakthrough Therapy Status in China for NSCLC Treatment#China#Chengdu#Kelun-Biotech#Pembrolizumab#sacituzumab_tirumotecan
Kelun-Biotech's Sacituzumab Tirumotecan Receives Breakthrough Therapy Status in China for NSCLC Treatment
Kelun-Biotech recently secured Breakthrough Therapy Designation for Sacituzumab Tirumotecan combined with Pembrolizumab, targeting NSCLC treatment in China.
third-news.com
January 5, 2026 at 9:31 AM
Kelun-Biotech's Sacituzumab Tirumotecan Receives Breakthrough Therapy Status in China for NSCLC Treatment#China#Chengdu#Kelun-Biotech#Pembrolizumab#sacituzumab_tirumotecan
Paclitaxel + PD-1/PD-L1 inhibitors: What works best for TNBC?
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
January 5, 2026 at 8:15 AM
Paclitaxel + PD-1/PD-L1 inhibitors: What works best for TNBC?
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
SICHUAN KELUN-BIOTECH SAYS SAC-TMT COMBO WITH PEMBROLIZUMAB GETS NMPA BREAKTHROUGH STATUS
January 5, 2026 at 12:01 AM
SICHUAN KELUN-BIOTECH SAYS SAC-TMT COMBO WITH PEMBROLIZUMAB GETS NMPA BREAKTHROUGH STATUS
si es niño etopósido si es niña adriamicina si es nb pembrolizumab
January 3, 2026 at 9:26 PM
si es niño etopósido si es niña adriamicina si es nb pembrolizumab
Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model https://www.medrxiv.org/content/10.64898/2026.01.02.25343295v1
January 3, 2026 at 12:25 AM
Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model https://www.medrxiv.org/content/10.64898/2026.01.02.25343295v1
Really impressive and quite unbelievable that Merck initially (post-aquisition of Organon) deprioritized pembrolizumab, nearly terminating it in early 2010 and preparing to out-license due to low oncology focus…
January 1, 2026 at 2:31 PM
Really impressive and quite unbelievable that Merck initially (post-aquisition of Organon) deprioritized pembrolizumab, nearly terminating it in early 2010 and preparing to out-license due to low oncology focus…
A big theme of AI in 2026 will be scientific acceleration; I anticipate:
1. AI playing a role in drug repurposing
2. Finding blockbusters in existing deprecated internal assets lists and in under appreciated post-M&A assets (following the stories of pembrolizumab, ibrutinib, to name a few)
1. AI playing a role in drug repurposing
2. Finding blockbusters in existing deprecated internal assets lists and in under appreciated post-M&A assets (following the stories of pembrolizumab, ibrutinib, to name a few)
January 1, 2026 at 2:30 PM
A big theme of AI in 2026 will be scientific acceleration; I anticipate:
1. AI playing a role in drug repurposing
2. Finding blockbusters in existing deprecated internal assets lists and in under appreciated post-M&A assets (following the stories of pembrolizumab, ibrutinib, to name a few)
1. AI playing a role in drug repurposing
2. Finding blockbusters in existing deprecated internal assets lists and in under appreciated post-M&A assets (following the stories of pembrolizumab, ibrutinib, to name a few)
In previously treated patients with #melanoma, pembrolizumab therapy is associated with durable long-term survival.
https://bit.ly/3YOgS0p
#melsm
https://bit.ly/3YOgS0p
#melsm
Pembrolizumab Associated With Durable Long-Term Survival in Previously Treated Melanoma
In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.
bit.ly
December 31, 2025 at 6:12 PM
In previously treated patients with #melanoma, pembrolizumab therapy is associated with durable long-term survival.
https://bit.ly/3YOgS0p
#melsm
https://bit.ly/3YOgS0p
#melsm
Updated results from the IND227 trial show that adding pembrolizumab to platinum-pemetrexed chemotherapy improved overall survival by 24% vs chemotherapy alone in advanced pleural mesothelioma, as presented by Dr. Scott Laurie.
Read more in ILCN: bit.ly/4jkXYbe
Read more in ILCN: bit.ly/4jkXYbe
Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma - ILCN.org (ILCN/WCLC)
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
bit.ly
December 31, 2025 at 3:27 PM
Updated results from the IND227 trial show that adding pembrolizumab to platinum-pemetrexed chemotherapy improved overall survival by 24% vs chemotherapy alone in advanced pleural mesothelioma, as presented by Dr. Scott Laurie.
Read more in ILCN: bit.ly/4jkXYbe
Read more in ILCN: bit.ly/4jkXYbe